Clene to Submit Briefing Book to FDA for ALS Treatment Approval
Clene (CLNN) and its subsidiary plan to submit a briefing book to the FDA in support of ALS treatment approval. This significant step could lead to a new treatment option for ALS patients.
This news matters as it provides insight into Clene's efforts to seek FDA approval for a potential new drug application for the treatment of ALS, a devastating neurodegenerative disease. The submission of the briefing book and the Type C interaction with the FDA represent significant steps in the regulatory process and could lead to the development of a new treatment option for ALS patients.
